Alzheimer’s drugs ‘make no meaningful difference to patients’, major review suggests
The Independent | Latest news and features from US, UK and worl…
April 16, 2026
Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK
Discussion in the ATmosphere